
COVID泚å°ã®å³æåžå Žæ€éãæ±ããæ°ããªæ»èªä»ãç ç©¶
å èšäºã¯ãã¡ããã/Click here to read the original article.
ç«åŠè ãã³ã©ã¹ã»ãã¥ã«ã·ã£ãŒãã¡ã¢ãªãŒã»ã¿ãªãŒã»ããŠãã³å士ãããŒã¿ãŒã»ããã«ããŒå士ãå·çããããã«ããŒè²¡å£ã®ç ç©¶ã¿ã€ãã«ã¯ãCOVID-19ã¯ã¯ãã³ã®åžå Žæ€å»ãæ±ãã声ãé«ãŸãïŒ ãªã¹ã¯ã¯çè«çå©çãã¯ããã«äžåããã§ããã
(åæ°ããèšè«ïŒ-ç«åŠè ãã³ã©ã¹ã»ãã¥ã«ã·ã£ãŒãã¡ã¢ãªãŒã»ã¿ãªãŒã»ããŠãã³å士ãããŒã¿ãŒã»ããã«ããŒå士ãå·çããããã«ããŒè²¡å£ã®ç ç©¶ãCOVID-19ã¯ã¯ãã³ã®åžå Žæ€å»ãæ±ãã声ãé«ãŸãïŒ Risks Far Outweigh Theoretical Benefits "ãšé¡ããè«æããScience, Public Health Policy and the Lawèªã«æ²èŒãããïŒ
èŠæšïŒäžçäžã§è¡ãããŠããCOVID-19ã¯ã¯ãã³æ¥çš®ãã£ã³ããŒã³ã¯ãå®å šæ§ãšæå¹æ§ã«é¢ããåºæ¬çãªåºæºãæºããããšãã§ãããé倧ãªå®³ããããã蚌æ ãç©ã¿éãªã£ãŠããã81,000人以äžã®å»åž«ãç§åŠè ãç ç©¶è ãé¢ä¿ããåžæ°ã240人ã®éžæã§éžã°ããæ¿åºé«å®ã17ã®å ¬è¡è¡çããã³å»åž«ã®å°éçµç¹ã2ã€ã®å·å ±åå ã17ã®å ±åå é¡å§å¡äŒããããŠäžçäžã®6ã€ã®ç§åŠçç ç©¶ããCOVID-19ã¯ã¯ãã³ã®åžå Žæ€éãæ±ããŠããã2024幎9æ6æ¥çŸåšãCDCã¯ãå»çåŸäºè ãŸãã¯è£œè¬äŒç€Ÿããã¯ã¯ãã³æå®³äºè±¡å ±åã·ã¹ãã ïŒVAERSïŒã«å ±åãããç±³åœå ã®æ»äº¡äŸ19,028ä»¶ãèšé²ããŠããããã®æ»äº¡ã«è£œåãé¢é£ããŠãããšèããŠãããVAERSã«å ±åãããCOVID-19ã¯ã¯ãã³ã«ããæ»äº¡ã®ç·æ°ïŒå šåå åœäž37,544ä»¶ïŒã¯ãéå»ã®ã¯ã¯ãã³ååã®ãªã³ãŒã«é床ãæå€§375,340ïŒ ã¯ããã«è¶ ããŠãããFDAã®ã¯ã©ã¹Iãªã³ãŒã«ã®åºæºïŒé節ãªå¥åº·è¢«å®³ãŸãã¯æ»äº¡ãåŒãèµ·ãã劥åœãªå¯èœæ§ã®ãã補åã«é©çšãããïŒãã¯ããã«è¶ ããŠãããéå°ãªæ»äº¡çãåŠå®çãªæå¹æ§ãåºç¯ãªDNAæ±æãææã»å ¥é¢ã»æ»äº¡ã®æžå°ãå®èšŒãããŠããªãããšãªã©ãããæäžç¶ç¶ã®æ ¹æ ã¯å€±ãããŠãããèŠå¶åœå±ã«å¯Ÿãããããã®çµ±äžçãªèŠè«ã¯ãããŒã¿ã®å®å šæ§ç£èŠãšãªã¹ã¯è»œæžã«ãããéå€§ãªæ¬ ç¹ãæµ®ã圫ãã«ããŠãããCOVID-19ã¯ã¯ãã³ãçŽã¡ã«åžå Žããæé€ããããšã¯ããããªã人åœã®æå€±ãé²ããçºçãã被害ã®èª¬æè²¬ä»»ãæããããã«æ¬¡ã®æ®µéã確å®ã«èžãããã«äžå¯æ¬ ã§ããã

COVID-19ãã¯ã¯ãã³ãã®åžå Žããã®å³ææ€éãæ±ããçµè«ã«è³ã£ããæã ããŸãšããéèŠãªèšŒæ ãé ã远ã£ãŠèª¬æããŠãããïŒ
COVID-19ã¯ã¯ãã³ã®åžå Žæ€éãæ±ããåºç¯ãã€çµ±äžããã声
81,000人以äžã®å»åž«ãç§åŠè
ãç ç©¶è
ãé¢ä¿ããåžæ°ã240人ã®éžæã§éžã°ããæ¿åºé«å®ã17ã®å
¬è¡è¡çããã³å»åž«ã®å°éçµç¹ã2ã€ã®å·å
±åå
ã17ã®å
±åå
é¡å§å¡äŒããããŠäžçäžã®6ã€ã®ç§åŠçç ç©¶ããCOVID-19ã¯ã¯ãã³ã®åžå Žæ€éãæ±ããŠããïŒ

ã¯ã¯ãã³æå®³äºè±¡å ±åã·ã¹ãã ïŒVAERSïŒ
2024幎9æ6æ¥çŸåšãCDCã¯ãå»çåŸäºè
ãŸãã¯è£œè¬äŒç€Ÿããã¯ã¯ãã³æå®³äºè±¡å ±åã·ã¹ãã ïŒVAERSïŒã«å ±åãããç±³åœã§ã®æ»äº¡äŸ19,028ä»¶ãèšé²ããŠãããçŽ1175人ãã¯ã¯ãã³æ¥çš®åœæ¥ã«ã1250人ãã¯ã¯ãã³æ¥çš®ç¿æ¥ã«æ»äº¡ããŠãããVAERSã§å ±åãããæ»äº¡äŸã¯ãæ§ããã«èŠç©ãã£ãŠã31åã®éå°å ±åã§ãããšæšå®ããããã€ãŸããCOVID-19ã¯ã¯ãã³æ¥çš®ã«ããã¢ã¡ãªã«ã®æ»äº¡è
æ°ã¯589,868人ïŒ19,028人Ã31人ïŒã«ãªãå¯èœæ§ãããã
éå°ãªæ»äº¡ç
VAERSãšãšãã«ã12ã®ç ç©¶ããCOVID-19ã¯ã¯ãã³ã®é壿¥çš®ãæ»äº¡çã®å¢å ã«ã€ãªãã£ãå¯èœæ§ãé«ãããšã瀺ããŠããã忀ã§ã¯ãCOVID-19ã¯ã¯ãã³ãšæ»äº¡ãšã®éã«å æé¢ä¿ãããå¯èœæ§ãé«ãããšã瀺ããŠãããå
šäžçã®COVID-19ã¯ã¯ãã³ã«ããæ»äº¡è
ç·æ°ã¯1,700äžäººãè¶
ããå¯èœæ§ãããïŒ

éå»ã®æ¯èŒ FDAã¯ã©ã¹Iãªã³ãŒã«ã®è¡šç€º
VAERSã«å ±åãããCOVID-19ã¯ã¯ãã³ã«ããæ»äº¡ã®ç·æ°ïŒå
šåå åœäž37,544人ïŒã¯ãéå»ã®ã¯ã¯ãã³ååã®ãªã³ãŒã«é床ãã¯ããã«è¶
ããæå€§375,340ïŒ
ã§ãã£ãã1955幎ãã«ãã¿ãŒã»ããªãªã»ã¯ã¯ãã³ã¯10äººã®æ»äº¡å ±åãåããŠçŽã¡ã«ååãããã1976幎ã®è±ã€ã³ãã«ãšã³ã¶ã»ã¯ã¯ãã³ã¯ã53äººã®æ»äº¡å ±åããã£ãåŸã«ååãããã1999幎ããã¿ã·ãŒã«ãã»ã¯ã¯ãã³ã¯15äŸã®è
žéå¡ã®å ±åãåãã補é äžæ¢ãšãªã£ããFDAã®ã¯ã©ã¹Iãªã³ãŒã«ã®åºæºã¯ãæ·±å»ãªå¥åº·è¢«å®³ãæ»äº¡ãåŒãèµ·ããåççãªå¯èœæ§ã®ãã補åã«é©çšããããããã®åºæºãã¯ããã«è¶
ããŠããïŒ

åŠå®çãªæå¹æ§
è€æ°ã®ç ç©¶ã«ãããCOVID-19ã¯ã¯ãã³æ¥çš®è
ã¯ã¯ã¯ãã³æªæ¥çš®è
ã«æ¯ã¹ãŠææãªã¹ã¯ãé«ãå¯èœæ§ãããããšã瀺ãããŠããïŒ
Eythorssonãã¯ã2å以äžã®ã¯ã¯ãã³æ¥çš®è
ã¯1å以äžã®æ¥çš®è
ã«æ¯ã¹ãŠåææãªã¹ã¯ã42ïŒ
é«ãããšãæããã«ããã
ChemaitellyãïŒãªãã¯ãã³äºçš®ã«å¯Ÿãããã¡ã€ã¶ãŒãã€ãªã³ããã¯ïŒBNT162b2ïŒã¯ã¯ãã³ãšã¢ããïŒmRNA-1273ïŒã¯ã¯ãã³ã®æå¹æ§ã¯èããäœäžãã7ãµæåŸã«ã¯æå¹æ§ããã€ãã¹ã¬ãã«ã«éãããšæšå®ããïŒ ãã¡ã€ã¶ãŒã§ã¯-17.8ïŒ
ãš-12.1ïŒ
ãã¢ããã§ã¯-10.2ïŒ
ãš-20.4ïŒ
ã§ãã£ãã
ShresthaãïŒCOVID-19ææãªã¹ã¯ã¯çšéäŸåçã«å¢å ãã3å以äžã®æ¥çš®ãåãã人ã¯ã¯ã¯ãã³æªæ¥çš®ã®äººã«æ¯ã¹ãŠ253ïŒ
ãªã¹ã¯ãé«ãããšãæããã«ãªã£ãã
FeldsteinãïŒã¯ã¯ãã³æ¥çš®ãåããŠããªã6ãµæãã4æ³ã®åã©ãã¯ãã¯ã¯ãã³æ¥çš®ãåããŠããªãåã©ããšæ¯èŒããŠãææããå¯èœæ§ã159ïŒ
é«ããçåæ§COVID-19ãçºçããå¯èœæ§ã257ïŒ
é«ãããšãæããã«ãªã£ãã
DNAæ±æ
COVID-19ã¯ã¯ãã³ã®DNAæ±æã¯ãè€æ°ã®è£œé æ¥è
ãã¯ã¯ãã³ãã©ãããã©ãŒã ãå°åã«ããã£ãŠå ±åãããŠãããæ¬§å·å»è¬ååºïŒEMAïŒãç±³åœé£åå»è¬åå±ïŒFDAïŒãªã©ã®èŠå¶æ©é¢ãæšå¥šããéŸå€ãã¯ããã«è¶
ããŠããïŒ

çµè«
COVID-19ã¯ã¯ãã³ã®å³æã¢ã©ããªã¢ã ãæ±ãã声ã¯ãèšçéã«éããæçµçã«è£œåãåžå Žããæé€ããããŸã§é«ãŸãç¶ãããšäºæ³ããããCOVID-19ã¯ã¯ãã³ã«é¢é£ããéå°ãªæ»äº¡çãåŠå®çãªæå¹æ§ãåºç¯ãªDNAæ±æã¯ååã«èšŒæãããŠãããFDAã®ã¯ã©ã¹Iãªã³ãŒã«ã®åºæºãã¯ããã«è¶
ããŠãããå€§èŠæš¡ã§æ±ºå®çãªç¡äœçºäºéç²æ€ãã©ã»ã察ç
§è©Šéšã§ã¯ãäž»èŠè©äŸ¡é
ç®ã§ããææäŒæãå
¥é¢ãæ»äº¡ã®æžå°ã蚌æãããŠããªãããããã£ãŠãCOVID-19ã¯ã¯ãã³ãéèŠãªèšåºè»¢åž°ãæžå°ããã广ãããããšã¯èšŒæãããŠããªããCOVID-19ã¯ã¯ãã³æ¥çš®ãæ¯æããç«å Žã¯ãé©åãªå»çè¡çºã«åããŠãããäœããã害ãäžããªããšããããã¯ã©ãã¹ã®èªãã«éåããŠããããã以äžã®ç ç²ãé²ãã説æè²¬ä»»ãæããããã®æ¬¡ã®ã¹ãããã確å®ã«èžãããã«ã¯ãCOVID-19ã¯ã¯ãã³ãçŽã¡ã«åžå Žããæé€ããããšãäžå¯æ¬ ã§ããã
ç Žæ» çãªCOVID-19ãã¯ã¯ãã³æ¥çš®ãããã°ã©ã ã«çµæ¢ç¬Šãæã¡ããã³ãããã¯ã®æ£çŸ©ã®æ®µéãéå§ã§ããããããã®ç ç©¶ãåºãå ±æããŠãã ããã